Business
OBD signs agreement with Agilent Technologies
OBD signs agreement with Agilent Technologies.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0865U\n Oxford BioDynamics PLC\n 31 March 2021\n \n \n \n \n Oxford BioDynamics signs supply and resale agreement with Agilent Technologies,\nand launches EpiSwitch® Explorer Array Kit for R&D use\n \n \n · \n \n Agilent Technologies to manufacture custom microarray based on OBD's proprietary probe sets for EpiSwitch® Explorer Array Kit\n \n \n \n · \n \n First commercial microarray kit available for high-resolution 3D genome profiling and biomarker discovery \n \n \n \n · \n \n Kit accompanied by EpiSwitch® Data Portal to enable powerful, intuitive analytics of research data and access to 3D genome knowledgebase\n \n \n \n · \n \n Launch of the EpiSwitch® Explorer Array Kit expands academic and clinical researcher access to OBD's EpiSwitch® technology platform following the launch of its EpiSwitch®CST (COVID-19 Severity Test)\n \n \n \n Oxford, UK - 31 March 2021-\n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch\n \n ®\n \n 3D genomics platform, and Agilent Technologies (NYSE: A), a global leader in the life sciences, diagnostics, and applied chemical markets, have signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch® Explorer Array Kit (\"Kit\").\n \n \n Under the terms of the agreement, Agilent will supply a custom-made SurePrint G3 CGH Microarray for the Kit, incorporating OBD's proprietary 3D genome probes. OBD has exclusive rights for supply and distribution of the Kit.\n \n \n Harnessing the strengths of Agilent's microarray technology and OBD's 3D genomic recognition algorithms, the EpiSwitch® Explorer Array Kit provides\n \n results at\n a high throughput, with high resolution in a fraction of the time. \n \n The Kit simultaneously interrogates almost 1 million 3D genomic sites, providing over ten times more high-value data points than conventional, costly, time-consuming methods of detection, which are limited by high noise to signal ratio. \n This creates a \n highly reproducible, \n unbiased map, which can be used to identify, evaluate, or monitor 3D genomic biomarkers.\n \n \n The newly launched Kit, which is for research use only, will enable a new level of whole genome screening, biomarker discovery, and profi...